Integrated BioPharma, Inc. filed a definitive proxy statement on October 28, 2026, inviting stockholders to vote on three proposals at the company's 2026 Annual Meeting of Stockholders scheduled for November 30, 2026.

Key Highlights

  • Meeting date and location: The 2026 Annual Meeting will be held at 9:00 a.m. local time on November 30, 2026, at the company's executive offices at 225 Long Avenue, Hillside, New Jersey 07205.
  • Record date and share count: Only holders of record as of October 15, 2026 may vote; 31,059,610 shares of Common Stock were outstanding and entitled to vote on that date.
  • Director election: Stockholders will be asked to elect Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders.
  • Equity Incentive Plan: Stockholders will vote on ratifying the 2025 Equity Incentive Plan, which would authorize the issuance of up to 7,500,000 shares of Common Stock, plus shares remaining available or becoming available through forfeitures under prior plans.
  • Auditor ratification: Stockholders will consider ratifying the appointment of CBIZ CPAs P.C. as independent auditor for the fiscal year ending June 30, 2027.
  • Board recommendation: According to the filing, the Board of Directors unanimously recommends that stockholders vote "FOR" all proposals.
  • Co-CEOs: The proxy letter was signed by Christina Kay and Riva Sheppard in their capacity as Co-Chief Executive Officers of Integrated BioPharma, Inc.

Three Votes Before Integrated BioPharma Stockholders in November 2026

Integrated BioPharma, Inc., a Delaware corporation headquartered in Hillside, New Jersey, operates in the biopharma sector and filed this definitive proxy statement with the Securities and Exchange Commission on October 28, 2026. The filing solicits votes from holders of the company's Common Stock, par value $.002 per share, on behalf of the Board of Directors. Each share of Common Stock carries one vote on each matter to be presented at the meeting, according to the proxy statement.

The first proposal asks stockholders to elect Class II directors for a three-year term running through the 2029 Annual Meeting. The second proposal concerns the company's 2025 Equity Incentive Plan, which the filing states would authorize up to 7,500,000 shares of Common Stock, along with any shares that remain available or become available through forfeitures under prior equity plans. The third proposal asks stockholders to ratify the appointment of CBIZ CPAs P.C. as the company's independent auditor for the fiscal year ending June 30, 2027. The Board of Directors, according to the filing, unanimously recommends a vote in favor of all three proposals.

Proxies may be submitted in person, by mail, or electronically, as described in the proxy statement. Stockholders whose shares are held in "street name" through a bank, broker, or other nominee are directed by the filing to follow instructions provided by their respective intermediary. The proxy materials, together with the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2026, were first mailed to stockholders on or about October 28, 2026. Dina L. Masi is identified in the filing as Secretary of the company.

What Was Disclosed

Integrated BioPharma, Inc. filed a definitive proxy statement covering its 2026 Annual Meeting. The filing discloses three voting proposals, a record date of October 15, 2026, a share count of 31,059,610, and a unanimous Board recommendation in favor of all proposals.